Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Seroquel data show significant improvement in compliance and cognition in schizophrenia

24.05.2005


Patients with schizophrenia who are treated with the atypical antipsychotic SEROQUEL (Quetiapine) show significantly superior rates of treatment compliance compared to patients treated with other atypical and typical antipsychotics, according to new data presented today at the American Psychiatry Association (APA) meeting in Atlanta, USA. Additional data presented today also showed improved cognitive functioning for patients with schizophrenia who are treated with SEROQUEL.



The compliance study is one of the few to compare both atypical antipsychotics with each other as well as with typical antipsychotics in schizophrenia. The findings show SEROQUEL to have the highest compliance rate of both typicals and atypicals, which was significantly (P<0.05) greater than that of risperidone (6% greater) and olanzapine (4% greater). These are welcome results in a patient environment where up to 50% of patients fail to comply with their prescribed medication, leading to an increased risk of relapse. This can result in the need for rehospitalisation and potential for high socioeconomic costs.

"Compliance with medication is fundamental to a successful treatment outcome in schizophrenia. However, all too often patients have to struggle with medications that cause distressing side effects such as extrapyramidal symptoms (EPS), increased prolactin levels leading to galactorroeha and sexual dysfunction, which makes complying with treatment a challenge many patients find too difficult to overcome" commented Dr Michael Riedel from the Munich University Hospital, Germany. "It is critical therefore that medications are not only effective in treating symptoms but are also well tolerated, which is where atypicals such as SEROQUEL are able to offer patients an improved outcome."


Cognitive Function

Two other studies presented at this year’s APA meeting compared the cognitive benefits of SEROQUEL and risperidone in patients with schizophrenia, demonstrating improvements in cognitive function among Seroquel-treated patients:

  • In a randomized, double-blind study of 44 patients, both SEROQUEL and risperidone improved cognition in patients with schizophrenia over a 6-week period. However, SEROQUEL (at a mean dose of 566.7 mg/day) produced significantly greater improvements in working and verbal memory than risperidone (p<0.01 and p<0.05 vs risperidone, respectively), with a significantly lower incidence of EPS, a highly distressing treatment-induced side effect
  • In an 8-week, double-blind, flexible-dose, parallel study randomizing 673 patients with schizophrenia, cognitive benefits of SEROQUEL (mean modal dose of 530 mg/day) and risperidone were compared. Both medications were associated with overall improvements in cognitive functioning (p<0.01) versus baseline.

"It is encouraging to see that SEROQUEL appears to be at least as effective as risperidone in improving cognitive function while also demonstrating a superior side effect profile in terms of extrapyramidal symptoms" continued Dr. Riedel. "Cognitive impairment is a serious symptom but one which is sometimes perceived as less important than some other symptoms of schizophrenia, such as hallucinations. However, recent studies have found that cognitive function is directly related to many areas of social interaction, and can limit an individual from being able to benefit fully from rehabilitation programmes. That is why treating these symptoms effectively is so important."

SEROQUEL has been licensed for the treatment of schizophrenia since 1997 and is available in 82 countries for the treatment of this condition. Results of recent studies show that 600mg/day is an efficacious SEROQUEL dose in patients with schizophrenia. SEROQUEL is also licensed in 63 countries for the treatment of mania associated with bipolar disorder, including the US, Canada and several European countries. To date, over 8 million people have been treated with SEROQUEL worldwide.

Sarah Fraser | EurekAlert!
Further information:
http://www.shirehealth.com

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

NASA's Fermi catches gamma-ray flashes from tropical storms

25.04.2017 | Physics and Astronomy

Researchers invent process to make sustainable rubber, plastics

25.04.2017 | Materials Sciences

Transfecting cells gently – the LZH presents a GNOME prototype at the Labvolution 2017

25.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>